Embecta Corp (FRA:JX7)

€ 11.6 -0.2 (-1.69%) Market Cap: 658.85 Mil Enterprise Value: 1.89 Bil PE Ratio: 10.28 PB Ratio: 0 GF Score: 26/100

Q1 2024 Embecta Corp Earnings Call Transcript
Feb 09, 2024

€18 (+12.50%)

Earnings
Embecta Corp at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Q4 2023 Embecta Corp Earnings Call Transcript
Nov 21, 2023

€15.2 (+1.33%)

Earnings
Embecta Corp at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Q3 2023 Embecta Corp Earnings Call Transcript
Aug 08, 2023

€19.3 (+0.52%)

Earnings
Embecta Corp at RBC Capital Markets Global Healthcare Conference Transcript
May 16, 2023
Q2 2023 Embecta Corp Earnings Call Transcript
May 12, 2023

€27.4 (-0.72%)

Earnings
Q1 2023 Embecta Corp Earnings Call Transcript
Feb 14, 2023

€26.8 (+3.08%)

Earnings
Embecta Corp at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Q4 2022 Embecta Corp Earnings Call Transcript
Dec 20, 2022

€30 (-3.23%)

Earnings
Embecta Corp at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Embecta Corp at Wells Fargo Healthcare Conference Transcript
Sep 08, 2022
Q3 2022 Embecta Corp Earnings Call Transcript
Aug 15, 2022

€31.4 (+15.10%)

Earnings
Q2 2022 Embecta Corp Earnings Call Transcript
May 13, 2022

Earnings

Embecta Corp at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 06:55PM GMT

Release Date Price: €31.8 (-2.45%)

Transcript

Cecilia E. Furlong

Morgan Stanley, Research Division - Equity Analyst

Good afternoon, and thank you for joining us for the second day of the Morgan Stanley Healthcare Conference. I'm Cecilia Furlong. I'm medical device analyst here at Morgan Stanley. It's my pleasure to have Embecta new spin-out first conference with us, invite the CEO, Dev Kurdikar; CFO, Jake Elguicze. Thank you both very much for being here.

Devdatt Kurdikar

Embecta Corp. - President, CEO & Director

Thank you, Cecilia, for having us, and thank you for those in the room that are here to listen to our story. And just sort of before we get started, you recognize that we might be making forward-looking statements and obviously risks and uncertainties associated with that. And in our filings and the SEC website, including our latest 10-Q, always refer to that if you have any questions. But with that, ready to jump in. Jake and I are here and wanting to answer your questions, Cecilia.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.